Back

Sacubitril/valsartan compared to ramipril in high risk post myocardial infarction patients stratified according use of mineralocorticoid receptor antagonists: Insight from PARADISE MI trial

26 August 2022 (08:00 - 19:30)
Organised by:
Congress Presentation Part of: Neprilysin inhibition: news and nuggets Pharmacotherapy ESC Professional Premium Access ESC Congress 2022

About the speaker

Photo
Professor Morten Schou

Herlev-Gentofte University Hospital, Gentofte (Denmark)

5 More presentations in this session

Presentation thumbnail
Effects of sacubitril-valsartan on clinical, echocardiographic and polygraphic parameters in patients affected by heart failure with reduced ejection fraction and sleep apnea
Doctor G. Armentaro (Catanzaro, IT)
Abstract Slides Video
Presentation thumbnail
ARNI effects in HFrEF. Risk reduction beyond LVEF
Doctor A. Boehmer (Wiesbaden, DE)
Abstract Slides Video
Presentation thumbnail
Prevalent and incident anaemia in PARADIGM-HF and effect of sacubitril/valsartan
Doctor J. Curtain (Dublin, IE)
Abstract Slides Video
Presentation thumbnail
Effects of angiotensin receptor-neprilysin inhibitors (ARNIs) on the glucose and fat metabolism biomarkers leptin and fructosamin
Doctor B. Ohnewein (Salzburg, AT)
Abstract Slides Video
Presentation thumbnail
Effect of sacubitril/valsartan on endothelial dysfunction and arterial stiffness in patients with chronic heart failure
Doctor V. Cassano (Catanzaro, IT)
Abstract Slides Video

Access the full session

Session thumbnail
Neprilysin inhibition: news and nuggets
Video

The Event

Event poster

ESC Congress 2022

26 August - 29 August 2022
You may be interested in
thumbnail
Congress Presentation
Sacubitril/valsartan vs. valsartan initiation in patients with heart failure and EF>40% who are naive to renin-angiotensin-system inhibitors: Insights from PARAGLIDE-HF
thumbnail
Congress Presentation
FINEARTS­HF: Blinded drug withdrawal
thumbnail
Congress Presentation
Safety and efficacy of early initiation of mineralocorticoid receptor antagonists in patients with worsening heart failure: a meta-analysis of randomized controlled trials

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources